Men Osteoporosis treatment. Men lose bone density just as women do. But their bone loss usually starts later in life than it does for women. Still if there are certain causes at work, men can begin to experience excessive bone loss at an early age. See: Causes of bone loss.
One of the problems physicians and their male clients experience is that there are fewer studies devoted to Men Osteoporosis treatment than there are studies that concern the treatment of women. This is beginning to change and this page offers one of the new studies concerning men.
This page begins with a report of one such study. The second half of the page offers a number of suggestions for increasing bone density.
Here is one of the studies concerning male Osteoporosis. This one was done in Japan:
Comparison of the Effects of Alendronate and Alfacalcidol on Hip Bone Mineral Density and Bone Turnover in Japanese Men Having Osteoporosis or Osteopenia with Clinical Risk Factors for Fractures. by Jun Iwamoto,corresponding author1 Yoshihiro Sato,2 Mitsuyoshi Uzawa,3 Tsuyoshi Takeda,1 and Hideo Matsumoto1
Purpose of the study: Although there have been many studies of post menopausal women, there are few studies about the effects of medication on men with low bone density. The aim of this study was to find the treatment effects of alendronate and alfacalcidol on hip BMD and bone turnover in Japanese men with osteoporosis or osteopenia who had clinical risk factors for fractures.
Materials and Methods One hundred twelve men with osteoporosis or osteopenia who had clinical risk factors for fractures (mean age: 71.4 years) were randomly divided into two groups of 56 patients each.
One group received alendronate (5 mg daily), the other group received alfacalcidol (1 µg daily) . The BMD of the total hip, urinary level of cross-linked N-terminal telopeptides of type I collagen (NTX), and serum levels of bone-specific alkaline phosphatase (BSAP) were measured during the 12-month-treatment period.
Forty-five patients in the alendronate group and 42 patients in the alfacalcidol group completed the trial.
Alendronate increased BMD (+2.3% at 12 months) following reductions in the urinary level of NTX (-46.4% at 3 months) and serum level of BSAP (-34.1% at 12 months).
The alfacalcidol group sustained BMD (-1.9% at 12 months) as well as the urinary level of NTX (+13.2% at 3 months) and serum level of BSAP (+1.8% at 12 months).
Conclusion The study confirmed that alendronate has better efficacy than alfacalcidol (active control) in increasing hip BMD and reducing bone turnover in Japanese men with osteoporosis or osteopenia whow have clinical risk factors for fractures.
Practical application: If your physician is considering prescription drug for your bone loss, alendronate may be a more efficacious choice than alfacalcidol.
Over the last few years I have tried to seek out studies concerning Men and Osteopenia, Osteoporosis. Of course a man can use many of the natural treatments and pharmaceuticals studied for women but there are some unique issues that men face when dealing with bone loss.
Here are some pages about Men Osteoporosis treatment , causes and possible natural remedies you might want to read:
Alternative medicine and bone loss